A Mab A Case | Study In Bioprocess Development

This content is suitable for a bioprocess engineering blog, a technical whitepaper, or an educational slide deck.

5.2 Column Packing Uniformity

The polishing CEX step requires a 45 cm diameter column (Vantage VL). Packing at scale reveals a consistent "tilt" in the bed height. After four failed packs, the team switches to dynamic axial compression and reduces the slurry concentration from 50% to 35%, achieving a HETP (Height Equivalent to a Theoretical Plate) of <0.05.

2.2 The Aggregation Anomaly (A Key Case Study Insight)

At Day 8 of the fed-batch culture, Size-Exclusion Chromatography (SEC) shows a spike in high-molecular-weight (HMW) species (aggregates) from 2% to 8%. This is a critical failure if not addressed. A Mab A Case Study In Bioprocess Development

Root Cause Analysis: Lowering the pH during harvest. As the culture ages, CO2 builds up, lowering pH to 6.7. Mab-X has a unique hydrophobic patch in the Fc region that is prone to unfolding at pH <6.8.

Solution: Automated pH control using 1M sodium bicarbonate (not NaOH, which would cause localized pH spikes). Additionally, the team adds 50 mM arginine to the harvest hold tank, which acts as a chaotropic agent to stabilize the antibody. This content is suitable for a bioprocess engineering

Phase 2: Upstream Processing – Scaling the Volume

Moving from a 2L benchtop bioreactor to a 2,000L production scale is where physics fights biology.

For mAb-X, the challenge was oxygen transfer. In a small flask, oxygen diffuses easily. In a massive stainless steel tank, the cells in the center can starve for oxygen if mixing isn't perfect. Main peak 73%

The Strategy: We moved from a conventional stirred-tank model to implementing a single-use bioreactor (SUB) strategy for the clinical launch.

• Why? SUBs offered flexibility and reduced cross-contamination risk.
• The Fix: To solve the oxygen issue at scale, we implemented a low-shear impeller design. This ensured the cells were kept in suspension without being ripped apart by mechanical force.

The outcome was a robust Process Performance Qualification (PPQ) run, where the culture achieved a final titer of 4.5 g/L—a benchmark that makes the manufacturing economically viable.

7. Formulation and Fill-Finish

• Formulation objectives: stability (chemical and physical), isotonicity, pH optimization, excipients (sugars, amino acids, polysorbates, buffers).
• High-concentration formulation challenges (viscosity, aggregation, subvisible particles).
• Container closure: vials vs pre-filled syringes; leachables/extractables testing; silicone oil impacts.
• Aseptic fill-finish vs sterile filtration; isolator technologies.

8. Analytical Development and Release Testing

• Method development: identity (peptide mapping), purity (SEC, CE-SDS), charge variants (cIEF/ion exchange), glycan analysis (LC-MS, HILIC-FLR), potency assays (cell-based).
• Release testing panel: purity, potency, endotoxin, sterility, HCP (ELISA), residual DNA (qPCR), aggregate content.
• Stability studies: ICH Q1A(R2) accelerated and long-term, forced degradation to define degradation pathways.
• Comparability strategy for process changes.

4.2 Charge variants (icIEF)

• Main peak 73%, acidic 15%, basic 12%. Within target.